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Prostate cancer (PCa) is one of the leading causes of cancer-related death in men. Despite considerable advances in prostate cancer
early detection and clinical management, validation of new biomarkers able to predict the natural history of tumor progression
is still necessary in order to reduce overtreatment and to guide therapeutic decisions. MicroRNAs are endogenous noncoding
RNAs which offer a fast fine-tuning and energy-saving mechanism for posttranscriptional control of protein expression. Growing
evidence indicate that these RNAs are able to regulate basic cell functions and their aberrant expression has been significantly
correlated with cancer development. Therefore, detection of microRNAs in tumor tissues and body fluids represents a new tool for
early diagnosis and patient prognosis prediction. In this review, we summarize current knowledge aboutmicroRNAderegulation in
prostate cancer mainly focusing on the different clinical aspects of the disease. We also highlight the potential roles of microRNAs
in PCa management, while also discussing several current challenges and needed future research.
1. Introduction
In developed Western countries, prostate cancer is the most
common solid tumor diagnosed in men and one of the
highest causes of cancer-related deaths after lung cancer [1].
Formany years, digital rectal examination (DRE) represented
the primary diagnostic test for prostate cancer detection. In
the late 1980s, prostate specific antigen- (PSA-) screening was
rapidly and widely adopted for PCa diagnosis [2]. However,
in spite of the significant improvement in early detection and
relapse assessment after radical prostatectomy, there is no
evidence that the PSA-test reduces the risk of death for the
disease. In fact, serum PSA level may be a consequence of
different variable events, such as benign prostatic hyperpla-
sia (BPH), inflammation of the gland, or pharmacological
therapy, and it is not correlated with either predicting tumor
aggressiveness or therapy responsiveness. Thus, PSA level
evaluation inevitably affects the false-positive rate of prostate
cancer detection, leading to overdiagnosis of patients who
present nonneoplastic alteration of the prostate gland or
clinically insignificant cancer [3, 4]. As a consequence of
its low predictive value, PSA screening has caused extra
diagnosis and overtreatment in cancer patients who are
subject to invasive or radical procedures with significant side-
effects and without effective benefits in quality of life. In the
last few years, several active surveillance protocols have been
approved for monitoring patients with low risk cancers [5].
This approach may strongly reduce patients’ overtreatment
and morbidity associated with surgery. However, a consid-
erable group of low-risk patients may experience tumor
progression. In this case, radical prostatectomy and radio-
therapy represent the standard treatment for localized high-
grade tumors [6, 7]. Nevertheless, a significant percentage of
radical-treated patients (30–35%) may develop biochemical
recurrence, with rising levels of PSA as a consequence of the
presence of cancer cells [8]. Since PCa depends on hormone
signaling for its growth and survival, androgen-deprivation
therapy represents the first-line therapy for this stage of the
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Figure 1: Representative scheme of prostate cancer tumor progression.
disease, with significant improvement in patient prognosis.
However, within 2 years of treatment a significant percentage
of these patients develop a castration-resistant form (CRPC)
of the disease, which is ultimately responsible for PCa
mortality [9]. Bone metastases occur in 70% of castration-
resistant patients and are associated with impairment in
quality of life due to the onset of skeletal-related events (SREs)
such as pathologic fractures, spinal cord compression, need of
surgery or radiotherapy on bone, hypercalcaemia, and bone
pain (Figure 1).
Therefore, the identification of predictive biomarkers able
to discriminate indolent tumors from aggressive ones would
be helpful in reducing the risk of overdiagnosis, avoiding
patients undergoing surgical/radiation therapies without any
clear clinical benefits but complex side effects. Moreover,
the consequent possibility to stratify patients on the basis of
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their responsiveness to treatment would be helpful in guiding
therapeutic decisions and in paving the way to personalized
medicine.
MicroRNAs (or miRs) are a family of small noncoding
RNA which are able to regulate gene expression at different
levels [10]. miRs are interspersed in the genome as indepen-
dent transcriptional units or within the open reading frame of
a specific gene. They are transcribed by the RNA polymerase
II and are processed through a series of endonucleolytic
cleavages, from nucleus to cytoplasm, in a mature form
of 22–25 nucleotide fragments which are able to regulate
mRNA spatial and temporal translation/degradation through
association with the RNA-induced silencing complex (RISC
complex). Generally, sequences recognized by miRs are
located in the 3󸀠-untranslated region (3󸀠-UTR) of coding
RNA but several studies demonstrated that microRNAs can
also bind to the 5󸀠-UTR [11] and to the coding sequence [12]
maintaining their regulatory properties. Furthermore, it has
been shown that these small RNAs play a dual role in cellular
regulation not only in inhibiting but also in activating gene
expression through direct binding to target RNA [13]. Based
on these observations, which highlight the complexity of this
fine-tune control of protein expression, it is not surprising
that microRNAs are involved in all basic cell processes, such
as proliferation, stemness maintenance, differentiation, and
apoptosis. Consequently, deregulation of their expression is
significantly correlated with the etiology of many diseases,
including cancer. The first evidence of microRNA’s role in
cancer came from the study of Calin and colleagues in 2002
[14]. They demonstrated that miR-15a and miR-16a were
either absent or downregulated in approximately 70% of
patients with B-cell chronic lymphocytic leukemia (B-CLL),
due to the deletion of chromosome region 13q14.
Circulating microRNAs represent the new expanding
field in the world of biomarker research. Indeed, they poten-
tially epitomize the perfect candidates for diagnostic and
prognostic purpose [15–17], since their expression reflects
the molecular profile of tumor origin [18], and they are
highly stable in body fluids and resistant to storage handling.
In fact, it has been demonstrated that serum miRs remain
stable after being subjected to severe conditions (boiling,
high/low pH levels, and freeze-thaw cycles) [19] and pre-
served in long-termbanked human serum samples. Although
the mechanisms by which circulating microRNAs are pro-
tected from RNase digestion have not yet been extensively
described, an increasing amount of evidence indicates that
miRs can form complexes with RNA-binding proteins [20]
or can be incorporated in cell-derived secreted exosomes
[21]. In the tumor environment, tumor-derived exosomes act
as carriers of genetic information and proteins destined to
recipient cells, where their production is finely regulated by
cancer cells. Thus, the incorporation of specific microRNAs
in these microvescicles would not be exclusively considered a
stochastic process due to the saturated levels of intracellular
RNA, but also a functionalmolecular programwhich permits
cancer cells to influence homeostasis of the surrounding
microenvironment. A recent study gave further evidence
of this mechanism, demonstrating that exosomes-mediated
transfer of miR-105 efficiently destroys tight junctions of the
vascular endothelial monolayer, prompting tumor metasta-
sis [22]. Currently, a variety of circulating RNA detection
methods is available but the most commonly used are Real-
Time PCR, microarray, and deep sequencing [23]. Although,
several technical biases are associated with each of these
detection protocols including contamination of microRNA
samples from other cellular sources (blood cells and stroma
cells), there is a lack of unequivocal endogenous control due
to the cell-free conditions, specificity of probes and enzyme
efficiency rate. Consequently, published studies report con-
flicting data indicating the necessity of a standardized and
robust method with universal parameters for circulating
microRNA analysis. From this point on, our knowledge on
microRNA-cancer connection has increased exponentially
but it is far from complete. However, it is evident that
microRNA analysis represents an innovative and specific
tool for the improvement of diagnostic, prognostic, and
therapeutic protocols. As a consequence of this assumption,
an increasing number of studies analyzing genomic alteration
of large cohorts of patients are evaluating also the microRNA
expression profiles, producing a high quantity of data which
could be useful to improve cancer management [24, 25]. Our
review focuses on miR clinical relevance and how much our
knowledge is expanding in this field. We selected all articles
reporting applications and results obtained analyzing patient-
derived samples, with a minor analysis of papers clearly
oriented towards basic research.
In order to provide a better understanding of recent
advances in miR-based biomarker validation for PCa, we
divided articles into three main topics: (1) diagnosis, (2)
prognosis, and (3) therapy.
2. MicroRNAs and PCa Diagnosis
In 2014, an estimate of 233,000 new cases of PCa will
be diagnosed with a 12% mortality rate (National Cancer
Institute, http://www.cancer.gov/). A significant percentage
of patients who experience tumor development before the
mean age represent the most difficult group to manage from
a clinical and psychological perspective. Several approaches
have been proposed to improve cancer diagnostic accuracy
of the PSA test, including the measurement of PSA velocity
(change over time), PSA density (ratio between protein
blood-level and prostate volume), and PSA-free and protein-
bound PSA levels. However, the clinical usefulness of these
strategies remains solely experimental. Sensitive biomarkers
are needed in order to reduce overdiagnosis, overtreatment,
biopsy side effects, and psychological stress [26]. Since
microRNA expression reflects the tumor of origin [27] and
that it has been correlated with prostate cancer development
and progression [28–30], miRs represent an intriguing and
promising approach for improving specificity of diagnosis.
To date, a distinctive microRNA signature able to distinguish
between healthy and diseased patients has not been found but
encouraging results have been obtained for PCa (Table 1). In
2006, Volinia and colleagues analyzed the expression profile
of 228 miRs in 56 prostate tumor tissues and 7 normal
controls [31]. Upregulation ofmiR-32, -26a, -181a, -93, -196a, -
25, -92, and let-7iwas confirmed also byAmbs [32] in a cohort
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Table 1: MicroRNAs associated with PCa diagnosis.
References Sample type miRs deregulated miRs selected as candidate biomarkers
Taylor et al.
(2010) [24]
113 PCa tissues
28 normal tissues Large screening study Taylor et al. 10.1016/j.ccr.2010.05.026
Volinia et al.
(2006) [31]
56 PCa tissues
7 normal tissues
39 upregulated
6 downregulated Volinia et al. 10.1073/pnas.0510565103;
Ambs et al.
(2008) [32]
60 microdissected tumor tissues
16 normal tissues
21 upregulated
21 downregulated
miR-32, miR-26a, miR-181a,
miR-93, miR-196a, miR25,
miR-92 and let-7i
↑
Porkka et al.
(2007) [38]
5 hormone-naı¨ve PCa tissues
4 HRPC tissues
4 BPH tissues
14 upregulated
37 downregulated
PCa: miR-16, miR-99 and let-7
family ↓
HRPC: miR-205, miR-100 and
miR-30 ↓
Ozen et al.
(2008) [43] 16 PCa tissues and 10 normal tissues
9 upregulated
76 downregulated Let-7, miR-30, miR-16 ↓
Martens-
Uzunova et al.
(2012) [44]
102 PCa tissues and
normal adjacent tissues 54 deregulated miR-205 ↓
Larne et al.
(2013) [45]
49 PCa tissues
25 normal tissues 7 deregulated
miR-96-5p, miR-183-5p ↑
miR-145-5, miR-221-5p ↓
(combined in miQ score)
Moltzahn et al.
(2011) [46]
Serum samples from PCa (𝑛 = 36) and
HD (𝑛 = 12)
6 upregulated
4 downregulated
miR-20b, miR-874,
miR-1274a, miR-1207-5p,
miR-93, miR-106a
↑
miR-223, miR-26b,
miR-30c, miR-24 ↓
Bryant et al.
(2012) [48]
Plasma samples from PCa (𝑛 = 78) and
HD (𝑛 = 28)
Urine samples from PCa (𝑛 = 118) and
HD (𝑛 = 17)
12 deregulated miR-107, miR-574-3p ↑
Srivastava et al.
(2013) [49]
40 PCa tissues and 40 normal adjacent
tissues.
Urine samples from PCa (𝑛 = 36)
and HD (𝑛 = 12)
2 downregulated miR-205, miR-214 ↓
Haj-Ahmad
et al. (2014) [50]
Urine samples from PCa (𝑛 = 8)
BPH (𝑛 = 12) patients and HD (𝑛 = 10)
17 deregulated
(only 7 selected for further analysis)
miR-1825 (only in PCa) ↑
miR-484 (in PCa and BPH) ↓
Schaefer et al.
(2010) [54] 76 PCa and adjacent normal tissues
5 upregulated
10 downregulated
miR-96, miR-182, miR-182∗
miR-183 and miR-375 ↑
miR-16, miR-31, miR-125b,
miR-145, miR-149, miR-181b,
miR-184, miR-205, miR-221,
miR-222
↓
PCa: prostate cancer; HRPC: hormone refractory prostate cancer; BPH: benign prostatic hyperplasia; HD: healthy donors, FFPE: formalin-fixed, paraffin-
embedded.
of 76 microdissected tissues including 60 tumor specimens
and 16 controls. In this study, the authors identified miR-101,
-30c, and -195 significantly upregulated in patients with
extraprostatic extension of cancer cells, suggesting a possible
role in predicting the evolution of the disease. Interestingly,
subsequent studies demonstrated the tumorigenic role of
miR-181a and miR-196 in several types of cancers, regulating
fundamental processes of malignant progression, such as
epithelial to mesenchymal transition (EMT) [33–35] and
invasive properties of the cells [36, 37].
In contrast to the previously described studies, Porkka
and colleagues demonstrated a significant downregulation
of microRNA expression levels correlating with PCa pro-
gression [38]. They evaluated a panel of 13 clinical prostate
tissues, including 4 BPH, 5 hormone-naı¨ve, and 4 hormone-
refractory PCa tumors. Their analysis revealed 37 downreg-
ulated and 14 upregulated miRs in PCa specimens. Among
downregulated microRNAs miR-16, miR-99, and let-7 family
are well known tumor-suppressor genes [39–42]. Interest-
ingly, reduced levels of miR-205, miR-100, andmiR-30 family
were observed only in hormone-refractory specimens sug-
gesting a hypothetical prognostic role for CRPC prediction.
Porkka’s profile discretely overlapped the one generated by
Ozen et al. [43]. In the latter study, the authors observed
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a significant reduction in miR levels in 16 prostate cancer
tissues compared with 10 normal prostate tissues. Among the
85 detectable miRs, 76 were downregulated, with a tendency
toward a more global downregulation of miRs in case of
early PSA recurrence. Stroma contamination could be one
possible explanation for widespread downregulation of miRs
in prostate cancer tissues. In fact, based on Ozen hypothesis,
normal stromal tissues express higher levels of miR and
thus, since cancers have less stroma than normal tissues, the
relative expression of miRs would appear to be decreased.
In line with this hypothesis, a more recent study confirmed
the general downregulation of microRNA expression corre-
lating with tumor progression [44]. The authors analyzed
a group of 102 patient-derived tissues through microarray.
Deregulation of 54microRNAswas found to clearly segregate
PCa specimens from normal adjacent tissues. Moreover, a
panel of 25 miRs (13 downregulated and 12 upregulated)
significantly correlated with poor clinical parameters, such
as Gleason score, incidence of metastases, and E-Twenty-
Six variant 1 (ETV1) alterations. Among the microRNAs
deregulated in the aforementioned study, 13 of them were
specifically analyzed by Larne and colleagues in a cohort
of FFPE prostatic tissues derived from 49 prostate cancer
patients and 25menwithout PCa [45]. Single-assay qRT-PCR
analysis revealed a signature of 7 deregulated microRNAs
(miR-96-5p, -183-5p, -183-3p, -145-5p, -205-5p, -221-5p, and
-409-5p) differentially expressed in PCa samples compared
with healthy control. The most significant upregulated (miR-
96-5p and miR-183-5p) and downregulated (miR-145-5p and
miR-221-5p) microRNAs were combined together in order
to obtain an miR index quote (miQ) which was able to
discriminate with high accuracy prostate cancer from non-
prostate cancer samples and to significantly predict tumor
aggressiveness and patients’ metastatic status. The predic-
tive value of miQ was further validated in four different
cohorts and, despite the differences in size, methodology,
and experimental design, the results obtained indicate that
miQ could represent a useful clinical biomarker reducing the
intervariability between samples.
In recent years, the discovery of circulating microRNAs
has resulted in a welcome and exciting change in biomarker
research. Particularly for prostate cancer, the possibility to
substitute invasive procedures, such as DRE and biopsy,
will certainly improve patient care. In 2011, Moltzahn et al.
compared microRNA serum levels of 12 healthy men and
36 PCa patients, divided in low risk, intermediate risk and
high risk based on the CAPRA score [46, 47]. Ten miRs
were substantially different between the healthy and all
malignant samples. Four were downregulated in the cancer
group (miR-223, -26b, -30c, and -24), and 6were upregulated
in the cancer group (miR-20b, -874, -1274a, -1207-5p, -93,
and -106a). Two miRs shown a linear correlation between
miR levels and cancer risk: miR-24 steadily decreased with
risk, whereas miR-106a steadily increased with risk. A similar
analysis was conducted by Bryant and colleagues in 2012
[48]. Using a qRT-PCR microarray panel, they analyzed
changing in microRNA expression profiles comparing 78
plasma samples derived from prostate cancer patients and
28 healthy controls. A signature of 12 microRNAs was
found to be significantly deregulated in PCa specimens and
the upregulation of miR-107 and miR-574-3p in localized
prostate cancer patients was also validated through single-
assay analysis. Notably, these twomicroRNAs were present at
significantly higher concentrations in the urine of men with
cancer compared with the control, indicating their potential
as noninvasive detectable biomarkers. Because of the ease of
collection, and the fact that prostate cells are directly released
into the urethra through prostatic ducts after DRE, urine
has become the future for noninvasive biomarker testing.
From the first study of Bryant, much effort has been devoted
to microRNA detection in patients’ urine seeing a rapid
expansion in this branch of research. In 2013, Srivastava
and colleagues analyzed the expressions of miR-205, miR-
214, miR-221, and miR-99b in 36 PCa patients and 12 age
and ethnicity matched healthy men [49]. miR-205 and miR-
214 were found to be significantly downregulated in cancer
samples compared with normal controls. More recently, a
cohort of 30 patient-derived urine samples (8 PCa patients,
12 BPH patients, and 10 healthy men) were analyzed for their
microRNA expression profiles [50]. From the deregulated
group, a panel of 7 miRs (miR-1234, -1238, -1913, -486-5p,
-1825, -484, and -483-5p) was selected for further analysis.
Single-assay evaluation showed a significant modulation of
miR-1825 andmiR-484 which were, respectively, upregulated
and downregulated in PCa samples compared with healthy
controls. In the BPH group, the same trend was observed
only for miR-484 whereas upregulation of miR-1825 was
found to be variable among the samples. The expression
pattern observed for these twomiRs was not confirmedwhen
patients were reevaluated two years later but combining data
from microRNAs deregulation and abnormal PSA levels,
the presence of prostate cancer was detected with 40% of
sensitivity and 81% of specificity. These promising results
testify that biomarkers detectable in body fluids, which can
be obtained in a noninvasivemanner, seem a good alternative
as possible screening tool.
3. MicroRNAs and PCa Prognosis
Patient prognosis prediction and follow-up monitoring still
represent the major challenges for clinical management
of prostate cancer. Prostate specific antigen-screening has
significantly improved tumor early detection and relapse
assessment after radical prostatectomy. However, serum PSA
level is not directly correlated with tumor aggressiveness or
therapy sensitiveness and its usefulness in reducing cancer
mortality rate is still under debate. MicroRNAs are gaining
considerable attention in the clinical setting because their
expression seems to accurately reflect the malignant evo-
lution of cancer cells [27]. Moreover, the high stability in
frozen and formalin-fixed and paraffin-embedded (FFPE)
tissues [51] combined with the possibility to detect these
small RNAs in body fluids, including serum, plasma, urine,
and saliva [21], make them highly attractive as potential
biomarkers. Based on this evidence, the number of studies
focusing on microRNA expression profiles in prostate cancer
has notably increased; however, results deriving from high-
throughput approaches produced partially contradictory
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reports. Lack of uniformity in proposed datasets for patient
stratification is in part due to the different study design,
underestimated treatments of the patients,methods of sample
collection, presence of contaminating cells, and sensitivity
and specificity of the platforms used. A summary of the most
prognostic significant miR has been reported in Table 2. As
a consequence of an abundant data in literature and extreme
complexity of the discussion in prognostic values of the data,
we divided this paragraph into two sections, one dedicated to
tissue and the other to fluid samples.
3.1. Prognostic MicroRNAs in PCa Tissues. The first attempt
to segregate patients through a microRNA profile screening
came from primary tumor analyses. Although it may be
questionable whether tumor tissue evaluation effectively
predicts changes observed in cancer cells, which are not only
spatial but also temporally regulated, the availability of a
limitless quantity of banked tumor samples makes them a
unique resource of information. The possibility of analyzing
preserved specimens for retrospective studies is particularly
advantageous for PCa, which is a slow-growing disease
requiring a long-scheduled follow-upmonitoring program to
obtain significant correlation between biomarker expression
and tumor progression.
3.1.1. Biochemical Recurrence (BCR) and MicroRNAs. Bio-
chemical recurrence is defined as de novo rising of PSA blood
levels after radical prostatectomy [52]. BCR is widely used as
an early end point to assess treatment success and frequently
prompts the initiation of secondary therapy in order to
reduce the risk of metastasis formation. Several studies were
attempted in order to establish a distinctive signature of
microRNAs able to stratify patients on the basis of their risk in
developing BCR. However, much controversy is still present
in the literature possibly due to several biases (study design,
sample collections, sensitivity, and specificity of platforms
used) which are common in translational research. In 2009,
Tong and colleagues analyzed the microRNA expression
profiles of 40 FFPE tumor tissues divided in early biochemical
relapse (𝑛 = 20) and nonrelapsed (𝑛 = 20) patients [53].
A signature of 16 microRNAs was able to segregate 75% of
analyzed relapsed patients, excluding 85% of patients with no
evidence of recurrence. Interestingly, single-assay qRT-PCR
validates the upregulation of miR-16, miR-135b, miR-194, and
miR-218 and downregulation of miR-140. In addition, the
authors showed a significant reduction of miR-23b, -100,
-145, -221, and -222 in prostate cancer tissues compared
with normal adjacent tissues, giving a diagnostic relevance
to their analysis. Another study performed by Schaefer
and colleagues [54], identified a microRNA signature of 10
miRs downregulated (miR-16, -31, -125b, -145, -149, -181b,
-184, -205, -221, and -222) and 5 upregulated (miR-96,
-182, -182∗, -183, and -375), differently expressed in tumor
tissues compared with normal adjacent tissues in a cohort of
76 prostate cancer patients. Further validation experiments
significantly correlate miR-31, -125b, -205, -222, and -96
with Gleason score and tumor stage. miR-96 expression was
also associated with BCR, indicating its potential role as
a prognostic biomarker. Notably, negative modulation of
miR-205 in recurrent samples was confirmed also by Hulf
et al. [55] who also demonstrated that this microRNA can
impair cell viability of cancer cells through modulation of
MED1 which has been correlated with castration-resistance
acquisition [56]. Due to the high number of studies demon-
strating the downregulation of miR-205 in patient-derived
samples, the role of miR-205 in PCa biology has been further
investigated in basic research, and recent reports demon-
strated that this microRNA exerts its tumor-suppressive
functions directly inhibiting the expression of the AR and
its downstream signaling cascade, c-SRC oncogene and the
antiapoptotic Bcl-2 protein [57–60]. Interestingly, Mittal
and colleagues observed that the delivery of gemcitabine-
conjugated and miR-205—complexed copolymers effectively
reverses chemoresistance, invasion, and migration of pan-
creatic cancer cells and inhibits tumor growth using in
vivo model [61]. All these results demonstrate the clinical
relevance of microRNAs as therapeutic tools for treating
cancer diseases and the significant advances in nanotech-
nology applied to medicine with a consequent increase in
the number of curative options for diseased patients. Among
downregulated microRNAs correlating with PCa cancer pro-
gression, let-7b and let-7c were demonstrated to be lost in
patients with shorter disease-free survival time [62]. This
result is in agreement with the demonstrated biological role
of let-7c in suppressing the expression of androgen receptor
(AR) in prostate cancer cells [63]. Interestingly, the let-7c/AR
interaction was not mediated by the canonical mechanism
of miR-mediated control of gene expression, but rather
through the targeting of v-myc avian myelocytomatosis viral
oncogene homolog (MYC), a recognized transcription factor
for the AR. The microRNA—mediated regulation of the
androgen receptor represents a new attractive way trying to
unravel the different pathways, in which this molecule plays
a pivotal role, and which are responsible for PCa progression.
However, since we focused mainly in the clinical aspects
of microRNAs biology, we decided not to discuss papers
lacking in analyzing clinical samples. Nevertheless, in order
to facilitate the comprehension of the importance of AR
targeting for future perspectives, we listed in Table 3 several
microRNAs involved in receptor regulation that have been
validated in basic research studies.
Several microRNAs play a dual role in prostate cancer
development and sometimes show opposite behavior in basic
research compared to translational studies. This is the case
of miR-100 and miR-221/-222. Basic research studies have
demonstrated the tumor-suppressor function for miR-100,
regulating several oncogenes, such as insulin-like growth
factor 2 (IGF2) andmechanistic target of rapamycin (mTOR)
[64, 65]. However, Leite et al. in 2011 [66] found a signif-
icant overexpression of these microRNAs in BCR prostate
cancer samples. The same scenario is applicable to miR-
221/-222 which are well known oncomiRs acting in various
tumor types [67] and regulating cyclin-dependent kinase
(CDK) inhibitors p27Kip1 and p57Kip2 [68, 69]. Moreover,
the work of Sun et al. [70] indicated that miR-221/-222 are
able to reduce the sensitivity of androgen-dependent cell
lines to dihydrotestosterone (DHT) resulting in androgen
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Table 2: MicroRNAs associated with PCa prognosis.
References Sample type Clinicalparameters miRs deregulated miRs selected as candidate biomarkers
Taylor et al.
(2010) [24]
113 PCa tissues
28 normal tissues Large screening study Taylor et al. 10.1016/j.ccr.2010.05.026
Martens-
Uzunova et al.
(2012) [44]
102 PCa tissues and
normal adjacent tissues
High risk
biochemical
recurrence
12 upregulated
13 downregulated
miR-19a, miR-130a,
miR-20a/106/93 ↑
miR-27, miR-143,
miR-221/222 ↓
Tong et al.
(2009) [53]
40 FFPE prostatectomy
Specimens
(20 without early BCR 20 with early
BCR)
Biochemical
recurrence
2 upregulated
4 downregulated
miR-135, miR-194
(40% of case) ↑
miR-145, miR-221,
miR-222 ↓
Schaefer et al.
(2010) [54]
76 PCa and adjacent
normal tissues
Biochemical
recurrence
5 upregulated
10 downregulated miR-96 ↑
Hulf et al. (2013)
[55]
149 PCa and 30 matched
normal tissues
Biochemical
recurrence 1 downregulated miR-205 ↓
Schubert et al.
(2013) [62]
BCR tissues and
disease-free tissues
Biochemical
recurrence 2 downregulated let-7b and let-7c ↓
Leite et al. (2011)
[66]
21 frozen BCR tissues
28 frozen disease-free tissues
Biochemical
recurrence 4 upregulated miR-100 ↑
Karatas et al.
(2014) [72]
82 PCa tissues
(41 BCR and 41 disease-free)
Biochemical
recurrence 3 downregulated miR-1, miR-133b ↓
Selth et al.
(2013) [102]
Serum samples from PCa patients
(BCR = 8)
disease-free = 8)
Biochemical
recurrence 3 upregulated miR-194 miR-146-3p ↑
Shen et al.
(2012) [87]
Plasma samples
from PCa (𝑛 = 82)
Castration
resistance 2 upregulated miR-21, miR-145 ↑
Jalava et al.
(2012) [90]
28 primary PCa tissues
14 CRPC tissues
12 BPH tissues
Castration
resistance
4 upregulated
3 downregulated
miR-32, miR-148a,
miR-590-5p, miR-21 ↑
miR-99a, miR-99b,
miR-221 ↓
Peng et al. (2011)
[94]
6 primary PCa tissues
7 bone metastatic tissues Metastasis 5 downregulated
miR-508-5p, miR-143,
miR-145, miR-33a,
miR-100
↓
Saini et al. (2011)
[95]
36 PCa tissues
8 metastatic tissues
8 normal tissues
Metastasis 1 downregulated miR-203 ↓
Mitchell et al.
(2008) [19]
Serum samples from metastatic PCa
(𝑛 = 25) and
age-matched HD (𝑛 = 25)
Metastasis 6 deregulated miR-141 ↑
Brase et al.
(2011) [100]
Serum samples from localized PCa
(𝑛 = 14) and metastatic PCa (𝑛 = 7) Metastasis 5 upregulated miR-141, miR-375 ↑
Bryant et al.
(2012) [48]
Serum samples from PCa (𝑛 = 72)
and metastatic PCa (𝑛 = 47)
Plasma samples from
PCa (𝑛 = 55) and
metastatic PCa (𝑛 = 24)
Metastasis 2 upregulated miR-141 and miR-375 ↑
Nguyen et al.
(2013) [103]
Serum samples from
localized PCa (𝑛 = 58) and
metastatic CRPC (𝑛 = 26)
Castration
resistance
3 upregulated
1 downregulated
miR-141, miR-375,
miR-378∗ ↑
miR-409-3p ↓
Zhang et al.
(2011) [88]
Serum samples from localized PCa
(𝑛 = 20), ADPC (𝑛 = 20), CRPC
DTX treated (𝑛 = 10) and BPH
(𝑛 = 6)
Castration
resistance 1 upregulated miR-21 ↑
FFPE: formalin-fixed, paraffin-embedded, BCR: biochemical recurrence,Pca: prostate cancer, CRPC: castration resistant prostate cancer, BPH: benign prostatic
hyperplasia, HD: healthy donors.
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Table 3: MicroRNAs regulating AR expression through direct
targeting.
References miRs involved in AR regulation
Hagman et al. (2013) [57] miR-205
Qu et al. (2013) [132] miR-185
Lin et al. (2013) [133] miR-31
Sikand et al. (2011) [134] miR-488∗
O¨stling et al. (2011) [135] miR-135b, miR-105b, miR-297,
miR-299-3p, miR-34a,
miR-34c, miR-371-3p, miR-421,
miR-499a, miR-499b, miR-634,
miR-654-5p, miR-9
independence acquisition. All these results contradict other
various studies reporting a significant downregulation of
miR-221/-222 expression in clinical samples representative
of PCa progression, including castration-resistant and bio-
chemical recurrence stages [38, 54, 71].More recently, Karatas
and colleagues described a significant downregulation of
miR-1 and miR-133b in recurrent compared with disease-
free patients [72]. As negative modulation of miR-1 is in
agreement with its tumor-suppressive role in prostate cancer
cells, modulating at least indirectly the expression of AR and
consequently their proliferative capabilities [73], downregu-
lation of miR-133b does not reflect recent reports in which its
dependence on androgen receptor and its role inmaintaining
cell viability is described [74, 75].
Altogether, these observations demonstrated the funda-
mental role of the biological context in whichmicroRNAs are
located but, at the same time, they stress the need to bridge
the gap between basic and translational research in order to
optimize the efforts toward improving cancer management.
3.1.2. Castration Resistant Prostate Cancer (CRPC) and
MicroRNAs. The concept of androgen deprivation for the
treatment of advanced prostate cancer was developed by
Huggins and Hodges in 1941 [76], and up until today, AR—
target therapy remains the first line treatment for this disease.
Almost all patients with advanced prostate cancer initially
respond to androgen deprivation therapy (ADT), showing
reduced PSA levels indicating a partial regression of residual
tumor. However, this type of condition is transitory and
invariably develops into a castration-resistant form which
leads to the formation of bone metastases in a significant
percentage of treated patients.
miR-21 is one of the most commonly deregulated
oncomiR in cancer [77]. Validated targets of miR-21 enclose
several genes mainly implicated in suppressing cell migration
and invasion, including programmed cell death 4 (PDCD4),
phosphatase and tensin homolog (PTEN), tropomyosin 1
(TPM1), sprouty homolog 2 (SPRY2) and the metallopro-
tease inhibitors TIMP3 and reversion-inducing-cysteine-rich
protein with kazal motifs (RECK) [78–83]. In PCa biology,
miR-21 expression increases togetherwith clinical parameters
(pathological stage, lymph node metastasis, capsular inva-
sion, organ confined disease and Gleason score) and it is
correlated with biochemical relapse, castration resistance and
metastasis formation [66, 84, 85]. Significantly, an increase
of miR-21 and miR-145 in D’Amico et al. score [86] high-
risk compared with low-risk patients, were described by
Shen et al. [87]. miR-21 was also described as predictive
biomarker of PCa progression since its blood-levels are
directly correlated with castration-resistant and metastatic
states [88]. One of the molecular mechanisms through which
miR-21 is able to regulate castration resistance process was
described recently. It involves the activation of the epithelial
to mesenchymal transition (EMT), through negative modu-
lation of tumor-suppressor BTG2 [89]. A further microarray
analysis identified a panel of miRs (miR-21, -32, -99a, -99b, -
148a, -221, and -590-5p) differentially expressed in castration-
resistant tumors compared to benign prostate hyperplasia
[90], and the functional study revealed that also miR-32
can inhibit BTG2 expression, suggesting a prognostic and
therapeutic role of this miR.
EMT seems to be a relevant process in escaping blockade
of androgen signals. miR-205 and miR-30 are two tumor-
suppressor microRNAs which can block the transition of
cancer cells towards an undifferentiated and more aggres-
sive state and both miRs have been negatively correlated
with prostate cancer malignant evolution. miR-30 reduces
expression levels of v-ets avian erythroblastosis virus E26
oncogene homolog (ERG) gene, which is one of the EMT-
associated effectors and, more importantly, is the most fre-
quently overexpressed oncogene in PCa activated by genomic
fusion of TMPRSS2 and ERG genomic loci [91]. In the same
way, miR-205 exerts its functions inhibiting the translation
of EMT-related genes zinc-finger-E-box-binding homeobox
1 (ZEB1) and 2 (ZEB2/SIP1) [92]. Moreover, its ectopic
expression in prostate cancer cell can impair dedifferentiation
and invasive properties acquisition blocking cancer associate
fibroblast (CAF) stimulation [93].
3.1.3. Bone Metastasis and MicroRNAs. Bone metastasis is
a common and severe complication of late-stage prostate
cancer. Complex interactions between tumor cells, bone cells,
and a milieu of components in their microenvironment
contribute to the osteolytic, osteoblastic, or mixed lesions
present in patients with advanced forms of PCa. Despite the
enormous efforts in unraveling the molecular mechanisms
regulating bone metastasis, this remains the most clinically
relevant but poorly understood aspect of the disease.
Analyzing a cohort of 13 patient-derived specimens (6
primary tumors and 7 bone metastatic PCa samples), Peng
and colleagues identified 5 microRNAs (miR-508-5p, -143,
-145, -33a, and -100) significantly decreased in bone metasta-
sis [94]. miR-143 andmiR-145 were also found to be inversely
correlated with serum PSA levels and Gleason score. Further
analysis in metastatic PC3 cell line demonstrated that over-
expression of these two miRs can reduce invasive capabilities
in increasing expression of E-Cadherin and consequently
impairing EMT activation.
Similar results were obtained for miR-203 whose expres-
sion was significantly attenuated in bone metastatic tissues
compared with normal tissues [95]. As a possible explanation
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for this modulation, the authors demonstrated that miR-203
controls the expression of the EMT factor ZEB2 and the
bone metastasis-related factor RUNX2. Moreover, this miR
has been associatedwith “stemness”maintenance owing to its
ability to inhibit the self-renewal-associated BMI1 polycomb
ring finger oncogene (BMI1) [96].
Although the significant association between miR-15/-16
cluster and bone metastasis formation has not yet been
confirmed, the role of these two microRNAs in PCa, and
other cancer types, has been extensively evaluated [39].
Alteration of the miR-15a and miR-16-1 translates into mul-
tiple tumor-promoting processes through the derepression
of key cell cycle-and apoptosis-related genes such as B-cell
CLL/lymphoma 2 (BCL2), wingless-type MMTV integration
site family-member 3A (WNT3A) and cyclin D1 (CCND1)
[97]. miR-15 and miR-16 have been found to be downregu-
lated also in cancer-associated fibroblasts (CAFs), promoting
malignant transformation and progression [98]. Reduced
miR-15a and -16-1 levels in CAFs result in FGF-2/FGFR1 axis
activation, which ultimately increases the tumor-supportive
capabilities of CAFs. Interestingly, delivery of synthetic miR-
16 was shown to be able to inhibit the growth of metastatic
prostate cancer cell lines in mouse bone [99]. This study
not only suggests that loss of miR-16 is a predictor factor of
metastatic colonization of bones but also that systemic deliv-
ery of miR-16 could represent a novel type of personalized-
therapy for treating patients with advanced prostate cancer.
3.2. Prognostic MicroRNAs in Patient Body Fluids Circulatory
System. The first report regarding the potential role of circu-
lating microRNAs as predictive biomarkers in PCa, was pub-
lished by Mitchell and colleagues in 2008 [19]. They analyzed
a panel of six candidates miRs (miR-100, -125b, -141, -143,
-296, and -205) in serum samples collected from25metastatic
prostate cancer patients and 25 age-matched healthy donors.
Among all the candidates, only miR-141 showed a significant
overexpression in PCapatients and a further analysis revealed
a moderate correlation with PSA levels. Similar results were
obtained by Brase et al., who demonstrated that miR-141 is
upregulated, together with miR-375, in sera of metastatic
patients compared with nonmetastatic samples [100]. Inter-
estingly, a significant deregulation of these two miRs was
found within the nonmetastatic group (low-risk versus high-
risk), indicating their potential role not only in prognosis
but also in early diagnosis. The upregulation of miR-141
and miR-375 in plasma and serum samples of metastatic
patients was also demonstrated in the aforementioned study
of Bryant et al. [48]. The biological role of miR-141 in
metastatic progression is still not fully understood, however
its expression has been demonstrated to be positively corre-
latedwith expression of alkaline phosphatase (ALP), amarker
of skeletal lesions and with increased level of bone metastatic
lesions [101].
Circulating microRNAs can also be associated with bio-
chemical recurrence and castration-resistant state acquisi-
tion. In 2013, Selth and colleagues revealed that miR-194
and miR-146-3p are overexpressed in sera of patients expe-
riencing biochemical relapse [102]. Interestingly, they found
also an increased level of miR-141, miR-375, and miR-200 in
these patients but further validation analyses did not confirm
a significant statistical relevance. On the contrary, in the
study conducted by Nguyen et al., miR-141 and miR-375 were
found strongly upregulated in a cohort of patients experi-
encing CRPC compared with localized PCa patients [103].
The same authors observed a significant correlation with
castration resistant state also for upregulated miR-378∗ and
for downregulated miR-409-3p. All these results, especially
those associated with miR-141 and miR-375, confirmed that
microRNA expression is extremely sensitive to molecular
changes in cancer cells.
Similarly, miR-21 has been reported to be upregulated in
CRPC patients. Zhang and colleagues analyzed a cohort of
6 BPH patients, 20 patients with localized PCa, 20 androgen-
deprivation therapy responsive patients and 10CRPCpatients
under docetaxel treatment, observing a positive correlation
between miR-21 levels and tumor progression [88]. Intrigu-
ingly, further observations in the CRPC cohort revealed
a direct correlation between high expression of miR-21
and unresponsiveness to chemotherapy, indicating that this
microRNA can distinguish between patients that will benefit
from the chemotherapeutic regimen and patients that will
not.
4. MicroRNAs and PCa Therapy
In addition to the absence of reliable diagnostic and prognos-
tic indicators, prostate cancer management is also impaired
by the lack of tools in guiding treatment assignment and
evaluating therapy response. Testosterone suppression rep-
resents the gold-standard first line treatment for men with
recurrent PCa, but the majority of tumors evolve towards
a castration-resistant state (CRPC) within 2 years. Despite
such tangible advances in local and systemic therapy, the
global management of PCa patients is still far from ideal, and
many questions concerning the optimal treatment of both
early and advanced forms still need to be addressed. The
administration of targeted or conventional therapies requires
accuracy of staging procedures and predictive biomarkers
of prostate cancer patients response. Hormone therapy for
prostate cancer is typically initiated using drugs that lower
serum testosterone, often in combination with competitive
androgen receptor antagonists, such as bicalutamide or
Casodex (CDX). The initial response to ADT is significantly
high in almost all treated patients but, within two years after
the initial treatment, a significant group of these patients fails
to be sensitive to this kind of treatment. Once this occurs, sec-
ondary hormone therapy is usually considered and it includes
different types of antiandrogens. Recently, different drugs
able to block androgen synthesis have been approved by the
FDA, such as (i) Abiraterone Acetate (AA) which is a potent
and selective inhibitor of CYP17, a protein required for andro-
gen biosynthesis in the testes, adrenal glands and prostate
tissue, and (ii) enzalutamide (Xtandi) which blocks the
effects of androgens in stimulating the growth of the prostate
cancer cells. Although initially effective at blocking tumor
growth, these therapies eventually fail, leading to a lethal
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Table 4: MicroRNAs associated with PCa therapy.
References Sample type Therapy miRs deregulated miRs selected as candidates
Josson et al.
(2008) [107]
LnCaP and
LnCaP C4-2B
Radiation
therapy 6 downregulated miR-521 ↓
Huang et al.
(2013) [110]
PC3 radiation
resistant cells
Radiation
therapy 1 upregulated miR-95 ↑
Ribas et al.
(2009) [85] LNCaP and LAPC-4
Hormone
therapy Overexpressed miR-21 ↑
Ottman et al.
(2014) [113]
LnCap CDX
sensitive cells
LnCap CDX
non-sensitive cells
Androgen
deprivation-
therapy
and casodex
21 upregulated
22 downregulated
http://www.molecularcancer.com
/content/13/1/1
Lehmusvaara
et al. (2013)
[114]
28 tumor tissues (𝑛 = 8 goserelin-treated
patients 𝑛 = 9 bicalutamide-treated
patients 𝑛 = 11 no treated-patients)
Endocrine
treatment 10 deregulated
miR-9 and miR-17 ↑
miR-218 ↓
Zhang et al.
(2011) [88]
Serum samples from localized PCa
(𝑛 = 20), ADPC (𝑛 = 20), CRPC DTX
treated (𝑛 = 10) and BPH (𝑛 = 6)
Docetaxel 1 upregulated miR-21 (in CRPC docetaxel resistant) ↑
Puhr et al.
(2012) [116] PC3 docetaxel-resistant cells Docetaxel 2 downregulated miR-200c, miR-205 ↓
Lin et al.
(2014) [118]
Serum and plasma samples from CRPC
PCa (𝑛 = 97) before and after therapy Docetaxel 46 deregulated
miR-200c, miR-200b, miR-146a,
miR-222, miR-301b, miR-20a
Kojima et al.
(2010) [119] PC3 paclitaxel-resistant cells Paclitaxel 1 downregulated miR-34a ↓
Fujita et al.
(2010) [121] PC3 and DU145 Paclitaxel 1 downregulated miR-148 ↓
PCa: prostate cancer; ADPC: androgen dependent prostate cancer; CRPC: castration resistant prostate cancer; BPH: benign prostatic hyperplasia; DTX:
docetaxel; CDX: casodex.
drug-resistant condition, castration-resistant state. For men
unresponsive to all forms of hormone treatment, the clinical
protocol actually provides different therapeutic approaches,
such as bisphosphonates administration, targeted therapies,
immunotherapy (Sipuleucel-T), and chemotherapy. Recently,
Radium-223 (Xofigo) has been approved as a new agent for
bone metastasis treatment. It is a radioactive element that
localizes in bone and its delivery may be effective at relieving
bone pain, preventing complications and prolonging life
expectancy [104]. The availability of biomarkers that dis-
criminate patients with indolent or aggressive tumors would
allow appropriate treatment early tumors doomed to become
aggressive andmetastatic. Newmolecular markers of therapy
response will be essential in driving therapy decision-making
of advanced tumors. Therefore, an overall improvement of
prostate cancermanagementwill need a comprehensive effort
to devise new tools for patient stratification and prediction
of therapy response. A future clinical use of miRs in the era
of individualized oncology may satisfy the requirement for a
patient-tailored therapeutic approach, based on personalized
therapeutic choices guided by patient’ molecular profiles.
Biomarker signature for patient stratification and therapy
decision is also expected to influence modern therapeutic
approaches to prostate cancer treatment such as neo- or
adjuvant systemic therapy, early chemotherapy, bisphospho-
nates, and targeted therapies. In fact, new targeted treatments
such as Denosumab, Abiraterone, Sipuleucel-T, androgen
receptor-, MET receptor-, and angiokinase-inhibitors will
highly benefit from molecular biomarkers that support the
decision-making process.
To date, an increasing number of published studies are
examining the role ofmicroRNAs as direct targets for prostate
cancer therapy (Table 4). However, the majority of studies
are based on prostate cancer cell line analysis which have no
valuable clinical relevance.
4.1. Radiation Therapy. Radiation therapy (RT) is one of the
treatment options for localized, high risk prostate cancer
tumors which cannot be treated with radical prostatectomy.
However, the risk of tumor regrowth following RT remains
high for a number of cancer patients, despite modern radi-
ation oncology techniques allowing specific delivery of high
radiation doses directly to the tumor volume [105, 106].Thus,
radiation resistance remains an open issue to be solved. The
role of microRNAs in RT is not yet fully understood and the
few studies analyzing the effects of X-rays administration in
changing miR expression profile come from basic research.
In 2008, Josson and colleagues [107] observed a considerable
downregulation of 6 miRs after irradiation of androgen-
dependent LnCaP and androgen-independent LnCaP C4-
2B cell lines. miR-521 was found to be downregulated to a
greater extent in both cell lines and its forced expression
increased LnCaP sensitivity to radiation-induced damages.
The observed phenotype was demonstrated to be a con-
sequence of Cockayne syndrome A (CSA), a DNA repair
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protein, and manganese superoxide dismutase (MnSOD), an
anti-apoptotic and antioxidant enzyme, regulation. All these
results suggest that miR-521 could be a new potential tool in
enhancing the efficacy of radiation treatment in PCa.
LnCaP cells were used as in vitro model for measuring
radiation effects also by Li et al. [108] who demonstrated that
overexpression of miR-106b is sufficient to override the cell-
cycle arrest induced by irradiation, through downregulation
of its validated target p21 [109]. Interestingly, this microRNA
was previously found upregulated in PCa specimens [32]
compared to normal control. Altogether, these results sug-
gest a potential therapeutic role of miR-106b suppression.
Another microRNA involved in radiation therapy resistance
is miR-95, which was found to be upregulated in radiation
resistant PC3 cell line compared to parental control [110].
A further analysis correlated resistance acquisition with
suppression of the sphingosine-1-phosphate phosphatase 1
(SGPP1) which was demonstrated to be directly regulated by
miR-95.
Despite this recent advance, little is known about the
regulatory effects of miRs on radiation resistance acquisition
and the molecular mechanisms involved. Consequently, a
comprehensive analysis on the role of microRNAs in treat-
ment responsiveness, especially in the clinical setting, is still
required to improve patient prognosis.
4.2. Hormone Therapy. Androgen deprivation therapy is the
standard treatment for patients who experience recurrence
after surgical resection of the prostate but, within two years
after the initial treatment, a significant group of these patients
develop incurable forms. Several microRNAs have been
associated with castration-resistant properties of the cells
through AR regulation. Overexpression of miR-21, which is
positivelymodulated by androgen receptor, is able to increase
proliferation abilities of androgen-dependent LnCaP and
LAPC-4 cell lines, overcoming cell cycle arrest induced by
testosterone deprivation and anti-AR treatment. Moreover,
the effect of miR-21 in evasion of castration-mediated growth
arrest was also confirmed in vivo, giving further evidence
of its role in PCa [85]. These results are in agreement with
translation studies which indicate miR-21 as one of the
microRNAs upregulated to major extent in prostate cancer
progression and suggest future implications for personalized
target therapies.
The opposite scenario has been described for the tumor-
suppressor miR-331-3p [111]. This microRNA is able to
reduce v-erb-b2 avian erythroblastic leukemia viral oncogene
homolog 2 (ERBB2) expression, a known oncogene whose
expression increases in advanced prostate cancer [112], and
to impair AR signaling pathway. Furthermore, miR-331-
3p increases the bicalutamide-induced inhibition of PSA
expression.
Although the significant results obtained for miR-21
and miR-331-3p, changing in their expression was not con-
firmed by Ottman and colleagues [113]. They analyzed dif-
ferent LnCaP-derived cell lines with different sensitiveness
to androgen withdrawal and CDX treatment. Comparing
microRNAexpression profiles, they found 21 upregulated and
22 downregulated miRs in both androgen-deprivation and
CDX administration conditions. Interestingly, deregulation
of several microRNAs was also confirmed in a study con-
ducted on patient samples derived from a neoadjuvant trial
consisting of 8 men treated with goserelin, 9 men treated
with CDX (𝑛 = 9), and 10 men untreated, prior to prosta-
tectomy [114]. Analysis of resected tumor tissues revealed an
upregulation of miR-9 and miR-17 and a downregulation of
miR-218 in agreement with Ottman’s study. Furthermore, the
authors identified a panel of miRs upregulated (miR-141, -
375, -210, etc.) and downregulated (miR-204, -100, -125b, etc.)
after hormone treatment, whose expression trend correlates
with poor prognosis.
Although we are moving toward translational medicine,
most studies still rely on prostate cancer cell lines as sur-
rogates for therapy response, which is not favorable. As the
attempts to unravel the molecular mechanisms responsi-
ble for castration-resistant state are producing intriguingly
results, it is evident that shifting this knowledge into the clin-
ical setting will provide a great benefit for patient outcome.
4.3. Chemotherapy. Chemotherapy is offered to suitable
patients with CRPC who have failed other treatment options.
However, 40–50% of patients with CRPC do not respond
substantially to chemotherapy, with the median duration of
response being 6–9 months [115].
EMT is an event frequently involved in chemother-
apy resistance of cancer cells. Puhr et al. [116] reported
that docetaxel-resistant prostate cancer cells underwent an
epithelial-to-mesenchymal transition during the selection
process, leading to diminished E-cadherin levels and upregu-
lation of mesenchymal markers. This phenotype was accom-
panied by a significant downregulation of miR-200c and
miR-205 which, once reexpressed, were able to rescue E-
cadherin and increase apoptotic rate of resistant cells. Dif-
ferent studies demonstrated the correlation of miR-205 with
enhanced cisplatin cytotoxicity, through negative modula-
tion of autophagic pathway, and with docetaxel-resistance
acquisition [116, 117]. Docetaxel-resistant cell lines were also
analyzed by Lin et al. in order to identify candidate circulating
microRNA biomarkers able to predict chemotherapy respon-
siveness [118]. After a first screening in naı¨ve and resistant
PC3 and DU145 cell lines, the authors selected a panel of
46 deregulated microRNAs which were further analyzed for
their expression in plasma and serum samples derived from
97 CRPC patients who were stratified in responder and
nonresponder groups. SixmicroRNAs (miR-200c, miR-200b,
miR-146a, miR-222, miR-301b, and miR-20a) were signifi-
cantly associated with therapy responsiveness on the basis
of their pretreatment levels and posttreatment expression
changing. Furthermore, 12 microRNAs (miR-200b, -200c,
-200a, -429, -21, -590-5p, -375, -132, -20a, -20b, -25, and -222)
were correlated with patient overall survival.
In PCa, miR-34a and miR-148 were associated with
paclitaxel resistance. Restored expression of miR-34a is able
to reduce proliferative capabilities of PC3 taxol-resistant cells
through modulation of sirtuin 1 (SIRT1) and antiapoptotic
BCL2 [119]. Interestingly, a similar effect was observed
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Table 5: MicroRNAs associated with stemness properties acquisi-
tion.
References miRs associated with stemness properties
Liu et al. (2012) [125] miR-34a
Saini et al. (2012) [126] miR-708
Huang et al. (2012) [127] miR-143 and miR-145
Hsieh et al. (2013) [129] miR-320
by Rokhlin et al. [120], whereby simultaneous overexpres-
sion of miR-34a and miR-34c resulted in increased p53-
mediated apoptosis in response to doxorubicin treatment
of LNCaP cells. The role of miR-148a in the response of
hormone-refractory prostate cancer cells to chemotherapy
was investigated by Fujita and colleagues [121]. Expression
levels of miR-148a were found to be lower in both PC3
and DU145 hormone-refractory prostate cancer cells, com-
pared to normal human prostate epithelial cells and LNCaP
hormone-sensitive prostate cancer cells. Furthermore, forced
expression of miR-148 in PC3 cells inhibited cell growth,
cell migration, and cell invasion and increased sensitivity to
paclitaxel through modulation of MSK1.
The theoretical concept of EMT is strictly correlated with
the new evidence demonstrating the presence within the
tumor mass of a stem-like subset of cells which are able to
self-renew and drive cancer development and progression
[122].Moreover, increasing evidence indicates that these cells,
which are called cancer stem cells (CSCs), are responsible for
drug resistance, tumor recurrence, and metastasis formation
[123, 124]. CSCs hypothesis suggests several possible explana-
tions for the mainly unsolved questions of treating patients
with cancer, such as local recurrence after treatment of solid
tumor by radiation or chemotherapy and development of
metastases that can appear many years after curative surgical
treatment of primary tumor. The first who analyzed the role
of microRNAs in stem-like prostate cancer cells were Liu and
colleagues in 2011 (Table 5) [125]. They demonstrated that
forced expression of miR-34a reduces purified CD44+ stem-
like prostate cancer cells and that it is sufficient to inhibit
clonogenic expansion, tumor regeneration, andmetastasis. In
contrast, downregulation ofmiR-34a in CD44− cell lines pro-
moted tumor development and invasive properties. Further-
more, the authors identified and validated CD44 itself as a
direct and functional target of this microRNA. CD44 protein
is also a direct target of the tumor-suppressor miR-708. As
a consequence of this regulation, ectopic expression of miR-
708 is able to inhibit the tumor-initiating capacity of prostate
cancer cells in vitro and to reduce tumor progression in
prostate cancer xenografts [126]. A further analysis revealed
that lowmiR-708 expressionwas associated significantly with
poor survival outcome, tumor progression, and recurrence
in patients with prostate cancer. Finally, miR-320, -143, -145,
and let-7 were also associated with suppression of stem-like
properties of the cells [125, 127–129].
Taken together, these results establish a strong ratio-
nale for developing microRNA-based therapy for targeting
prostate CSCs in order to eradicate the basal core of tumors
and restore patient responsiveness to current pharmacologi-
cal treatment.
5. Conclusion
In the last decade, the advent of PSA screening improved PCa
detection but its low predictivity caused overdiagnosis and
overtreatment with consequent increase in patient morbidity
[5]. In addition, analysis of PSA blood levels does not
represent per se an unequivocalmethod to assess the presence
of prostate adenocarcinoma since it can be influenced by
nonneoplastic alterations.Thus, patients necessarily undergo
multiple local biopsies which up to now represent the
standard approach for diagnosis. However, it is possible that
also after anatomical and pathological evaluation of tissue
biopsies, diagnosis still remains uncertain with consequent
psychological stress for the patients. In this context, a lot of
effort has been dedicated trying to improve our capabilities
to manage cancer diseases and the exponential development
of innovative technologies creating the bases for translating
results from basic research to a real patients’ clinical benefit.
Thus, the role of microRNAs in prostate cancer provides a
solid rationale for their further evaluation in clinical practice.
In fact, microRNAs’ ability to regulate almost all cellular pro-
cesses makes them an attractive tool for diseasemanagement,
including cancer. Furthermore, their high stability in patient-
derived tissues and body fluids provides the possibility to
perform noninvasive screening which are able to evaluate
patients’ natural history of the disease with high accuracy,
due to the fact that microRNAs are representative of all
tumor molecular changing during the time. The increasing
sensitiveness and reliability of new technologies assure the
analysis starting from low amount of material giving the
opportunity to create new accurate and noninvasive tests. In
particular for prostate cancer, the identification ofmicroRNA
signatures, correlating specifically with tumor properties,
represents a new source of specific biomarkers and the future
advantage for both diagnosis and prognosis is clearly evident.
The increasing amount of studies analyzing miR expression
profiles is a consequence of this assumption with the spe-
cific aim to identify innovative biomarkers able to distin-
guish nonneoplastic alteration of the prostate from localized
tumors and indolent from aggressive tumors, in order to
decrease the incidence of overdiagnosis/overtreatment and
to guide therapeutic decision, respectively. In the era of
personalized therapy, it is imperative to find new biomarkers
able to mirror cancer aberrant molecular setting and to
guarantee monitoring cancer progression during early and
late stages.Thus, the possibility to create a personalmolecular
profiling of the tumors may determine the creation of an
individual therapeutic protocol optimizing therapy benefit
and reducing secondary effects of nonnecessary treatment.
Finally, advancement in delivery systems (liposomes and
nanoparticles among others) and molecule stability (LNA-
modified anti-miR and microRNA-mimics) have paved the
way for the use ofmicroRNAs as effective drugs for integrated
therapy [130, 131] and several clinical trials testing the efficacy
ofmicroRNAs are ongoing.This fieldmay offer a great oppor-
tunity in terms of application in tumor disease, including
PCa. Overall, improving prostate cancer management will
provide both individual and social benefits due to themassive
social impact of this malignancy, allowing at the same time a
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significant rationalization of financial resources dedicated by
the national health system.
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